Fennec Pharma's PEDMARK® Drives Growth, Expands Globally Amidst Rising Pediatric Cancer Rates
- $12.5 million: Q3 2025 net product sales for PEDMARK®, a 79% year-over-year increase
- 79% growth: Year-over-year increase in PEDMARK® sales, reflecting rising adoption in pediatric cancer treatment
- Cisplatin risk mitigation: PEDMARK® reduces irreversible hearing loss in children undergoing cisplatin chemotherapy
Experts in pediatric oncology widely endorse PEDMARK® as a critical advancement in protecting children from cisplatin-induced hearing loss, enhancing long-term quality of life without compromising cancer treatment efficacy.
Fennec Pharma's PEDMARK® Drives Growth, Expands Globally Amidst Rising Pediatric Cancer Rates
NEW YORK, NY – November 13, 2025
A Breakthrough in Pediatric Oncology Care
Fennec Pharmaceuticals is experiencing a period of robust growth, driven by the success of its lead product, PEDMARK® (sodium thiosulfate injection). The company recently announced strong Q3 2025 financial results, reporting $12.5 million in net product sales – a 79% year-over-year increase. This growth is particularly noteworthy as it demonstrates the increasing recognition and adoption of PEDMARK® as a crucial component in the treatment of pediatric cancer patients undergoing cisplatin chemotherapy. Cisplatin, while effective in fighting numerous cancers, carries a significant risk of irreversible hearing loss – a devastating side effect for young patients whose cognitive and emotional development can be profoundly impacted.
“The impact of hearing loss on a child's life is immeasurable,” explains one pediatric oncologist, speaking anonymously. “It affects their ability to learn, communicate, and socialize. PEDMARK® offers a critical layer of protection, allowing us to deliver life-saving treatment without compromising their long-term quality of life.